This suggests that patient trials co-titrating SHP2 inhibition with ALK inhibition may be a way to produce a specific inhibitory effect on cancer cell growth, whilst minimising toxicity in ALK-negative cells in the body. The gene discussed is PTPN11; the disease is cancer.